In clinical oncology, treatment advances for HER2-positive and triple-negative breast cancer illustrate core principles of targeted and combination therapy: tyrosine kinase inhibitors and antibody-drug conjugates extend disease control in heavily pretreated HER2-positive metastatic disease, including intracranial activity, while immune checkpoint inhibition added to neoadjuvant chemotherapy can improve pathologic complete response in triple-negative disease. These findings sit within the broader framework of biomarker-guided treatment selection and risk stratification, including the use of genomic recurrence-risk assays to inform adjuvant chemotherapy decisions in early-stage, hormone-receptor-positive disease.
In clinical oncology, treatment advances for HER2-positive and triple-negative breast cancer illustrate core principles of targeted and combination therapy: tyrosine kinase inhibitors and antibody-dr…